Lineage Cell Therapeutics (LCTX) EBIT Margin (QoQ) (2010 - 2026)

Lineage Cell Therapeutics (LCTX) EBIT Margin (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lineage Cell Therapeutics 251.15 Mn 188.44 Mn 1.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -34,108.00
Dec 31, 2025 376.00
Sep 30, 2025 61,252.00
Jun 30, 2025 -28,228.00
Mar 31, 2025 -25,492.00
Dec 31, 2024 -7,656.00
Sep 30, 2024 31,508.00
Jun 30, 2024 4,460.00
Mar 31, 2024 -15,659.00
Dec 31, 2023 23,343.00
Sep 30, 2023 -38,234.00
Jun 30, 2023 12,259.00
Mar 31, 2023 6,831.00
Dec 31, 2022 -17,153.00
Sep 30, 2022 -8,216.00
Jun 30, 2022 2,914.00
Mar 31, 2022 -6,565.00
Dec 31, 2021 24,498.00
Sep 30, 2021 108,136.00
Jun 30, 2021 42,026.00